Bookbot

Modern Strategy for Preclinical Pharmaceutical R&D

Towards the Virtual Research Company

Más información sobre el libro

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.

Compra de libros

Modern Strategy for Preclinical Pharmaceutical R&D, David Cavalla, John Flack, Richard Jennings

Idioma
Publicado en
1997
product-detail.submit-box.info.binding
(Tapa dura)
Te avisaremos por correo electrónico en cuanto lo localicemos.

Métodos de pago

Nadie lo ha calificado todavía.Añadir reseña

Título
Modern Strategy for Preclinical Pharmaceutical R&D
Subtítulo
Towards the Virtual Research Company
Idioma
Inglés
Editorial
Wiley
Publicado en
1997
Formato
Tapa dura
Páginas
228
ISBN10
0471971170
ISBN13
9780471971177
Serie
Descripción
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.